Antibacterial Drug Discovery Conference in Amsterdam Featuring Industry Advances to Be Held June 28-29, 2001

Apr 16, 2001, 01:00 ET from Strategic Research Institute

    AMSTERDAM, Netherlands, April 16 /PRNewswire/ -- The world industrial and
 academic antimicrobial communities will convene in Amsterdam to attend the
 "Antibacterial & Antifungal Drug Discovery & Development Summit" on
 June 28-29, 2001, just before the International Chemotherapies Conference
 (ICC), announces Strategic Research Institute.
     The meeting features many of the top industrial and academic scientists in
 the fields of applied antibacterial and antifungal discovery, with a number of
 compounds in late stage clinical development to be presented.
     Among the antibacterial compounds to be presented are Lilly's Oritavancin
 to be presented by Dr. Luis-Emilio Garcia, Wyeth Ayerst's Tigilcycline to be
 presented by Dr. Steve Projan, and Cubist's Daptomycin to be presented by
 Dr. Frank Tally.
     Exciting new antifungal compounds to be presented are Fujisawa's
 Micafungin to be presented by Dr. Donald Buell, Merck's Cancidas to be
 presented by Dr. Ken Bartizal, and Schering Plough's Posaconazole to be
 presented by Dr. Geoffrey M. Mukwaya.
     The broad-based meeting follows on the success of this meeting series held
 annually in the United States since 1995; the 2001 meeting, held in Princeton,
 NJ in March, was attended by over 250 scientists and executive managers from
 around the world.
     Other presenting companies and academic institutions are Aventis
 Pharmaceuticals, Institut Pasteur, GlaxoSmithKline, Kosan Biosciences,
 The R.W. Johnson Pharmaceutical Research Institute, Ribotargets, GPC Biotech,
 Versicor, Procter & Gamble, and Quorex Pharmaceuticals.
     Drs. David M. Livermore of Central Public Health Laboratory and Frank C.
 Odds of the University of Aberdeen will keynote the antibacterial and
 antifungal sections, respectively.  Dr. Livermore's keynote is entitled "The
 Trouble With Gram Negatives" while Dr Odds' is entitled "New Antifungal
 Agents: Filling a Clinical Need".
     To request the agenda, please contact Bebe Anderson at
 banderson@srinstitute.com or 212-967-0095, ext. 255, or Sumeet Hora at
 shora@srinstitute.com or 212-967-0095, ext. 261.  Please include your
 affiliation, mailing address, and fax number.
     To obtain exhibition details or to inquire about sponsoring a luncheon,
 the reception, or totebag giveaway, please contact Mark Alexay at
 malexay@srinstitute.com
 
     CONTACT:  Bebe Anderson, 212-967-0095, ext. 255, or
               banderson@srinstitute.com, or Sumeet Hora, 212-967-0095,
               ext. 261, or shora@srinstitute.com, both of Strategic Research
               Institute.
 
 

SOURCE Strategic Research Institute
    AMSTERDAM, Netherlands, April 16 /PRNewswire/ -- The world industrial and
 academic antimicrobial communities will convene in Amsterdam to attend the
 "Antibacterial & Antifungal Drug Discovery & Development Summit" on
 June 28-29, 2001, just before the International Chemotherapies Conference
 (ICC), announces Strategic Research Institute.
     The meeting features many of the top industrial and academic scientists in
 the fields of applied antibacterial and antifungal discovery, with a number of
 compounds in late stage clinical development to be presented.
     Among the antibacterial compounds to be presented are Lilly's Oritavancin
 to be presented by Dr. Luis-Emilio Garcia, Wyeth Ayerst's Tigilcycline to be
 presented by Dr. Steve Projan, and Cubist's Daptomycin to be presented by
 Dr. Frank Tally.
     Exciting new antifungal compounds to be presented are Fujisawa's
 Micafungin to be presented by Dr. Donald Buell, Merck's Cancidas to be
 presented by Dr. Ken Bartizal, and Schering Plough's Posaconazole to be
 presented by Dr. Geoffrey M. Mukwaya.
     The broad-based meeting follows on the success of this meeting series held
 annually in the United States since 1995; the 2001 meeting, held in Princeton,
 NJ in March, was attended by over 250 scientists and executive managers from
 around the world.
     Other presenting companies and academic institutions are Aventis
 Pharmaceuticals, Institut Pasteur, GlaxoSmithKline, Kosan Biosciences,
 The R.W. Johnson Pharmaceutical Research Institute, Ribotargets, GPC Biotech,
 Versicor, Procter & Gamble, and Quorex Pharmaceuticals.
     Drs. David M. Livermore of Central Public Health Laboratory and Frank C.
 Odds of the University of Aberdeen will keynote the antibacterial and
 antifungal sections, respectively.  Dr. Livermore's keynote is entitled "The
 Trouble With Gram Negatives" while Dr Odds' is entitled "New Antifungal
 Agents: Filling a Clinical Need".
     To request the agenda, please contact Bebe Anderson at
 banderson@srinstitute.com or 212-967-0095, ext. 255, or Sumeet Hora at
 shora@srinstitute.com or 212-967-0095, ext. 261.  Please include your
 affiliation, mailing address, and fax number.
     To obtain exhibition details or to inquire about sponsoring a luncheon,
 the reception, or totebag giveaway, please contact Mark Alexay at
 malexay@srinstitute.com
 
     CONTACT:  Bebe Anderson, 212-967-0095, ext. 255, or
               banderson@srinstitute.com, or Sumeet Hora, 212-967-0095,
               ext. 261, or shora@srinstitute.com, both of Strategic Research
               Institute.
 
 SOURCE  Strategic Research Institute